Data Sheet (Cat.No.T5830)

TargetMol

SKLB-23bb

Chemical Properties



CAS No. : 1815580-06-3

Formula: C21H24N4O4

Molecular Weight: 396.44

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	SKLB-23bb is an orally bioavailable HDAC6-selective inhibitor and also has microtubule-disrupting ability.
Targets(IC50)	HDAC
In vivo	In vivo efficacy evaluations of colorectal HCT116, acute myelocytic leukemia MV4-11, and B cell lymphoma Romas xenografts, SKLB-23bb more effectively inhibited the tumor growth than SAHA even at a 4-fold reduced dose or ACY-1215 at the same dose. SKLB-23bb is a potent oral anticancer candidate for selective HDAC6 inhibitor.

Solubility Information

Solubility	DMSO: 32 mg/mL (80.72 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.04 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.5224 mL	12.6122 mL	25.2245 mL
5 mM	0.5045 mL	2.5224 mL	5.0449 mL
10 mM	0.2522 mL	1.2612 mL	2.5224 mL
50 mM	0.0504 mL	0.2522 mL	0.5045 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Yang Z , Wang T , Wang F , et al. Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazolin as the Cap for the Treatment of Cancer[J]. Journal of Medicinal Chemistry, 2015, 59(4):1455-1470.